Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
7/16/2024 | Mkt Perform | JMP Securities | |
6/28/2024 | Outperform | William Blair | |
5/9/2023 | $55.00 | Buy | BTIG Research |
10/26/2021 | $65.00 → $53.00 | Hold → Buy | Craig Hallum |
7/13/2021 | $95.00 → $54.00 | Outperform | Raymond James |
JMP Securities analyst Constantine Davides initiates coverage on Simulations Plus (NASDAQ:SLP) with a Market Perform rating.
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicalsSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded research project with the International Collaboration on Cosmetics Safety (ICCS) to evaluate the use of physiologically-based kinetic (PBK) modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients.In a competitive bidding process, Simulations Plus was selected for its propos
Craig-Hallum analyst Matt Hewitt reiterates Simulations Plus (NASDAQ:SLP) with a Buy and maintains $56 price target.
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform
William Blair initiated coverage of Simulations Plus with a rating of Outperform
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O'Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024. Mr. O'Connor will host one-on-one and small group meetings throughout the day. This event is expected to include more than 200 companies as well as a preeminent group of investor attendees, including chief investment officers, portfolio managers and analysts. For more information a
Announces leadership appointments for newly structured business units Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future growth following the Company's recent acquisitions. These actions will be effective August 30, 2024. "Over the past year, we made two key acquisitions, including the largest in our corporate history," said Shawn O'Connor, Chief Executive Officer. "As a result, we have doubled our total addressable market, developed a
Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI) Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, has released the latest version of its flagship quantitative systems toxicology (QST) platform, DILIsym® version X. "Modeling and predictions regarding drug efficacy are critical in the drug development process—but so are predictions regarding safety," said Dr. Brett Howell, President of Quantitative Systems Pharmacology (QSP) Solutions at Simulations Plus. "We know ther
8-K - Simulations Plus, Inc. (0001023459) (Filer)
10-Q - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increase
Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the inves
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18.3 million Software revenue increased 11% to $11.6 million, representing 63% of total revenue Services revenue increased 27% to $6.7 m
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among